{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:07:52Z","timestamp":1793995672248,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003397","name":"Huazhong University of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.biomaterials.2020.119987","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T05:14:53Z","timestamp":1584594893000},"page":"119987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis"],"prefix":"10.1016","volume":"245","author":[{"given":"Lisen","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2020.119987_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.119987_bib2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0361-9230(03)00095-9","article-title":"Neuropathology of multiple sclerosis - new concepts","volume":"61","author":"Korneck","year":"2003","journal-title":"Brain Res. Bull."},{"issue":"6","key":"10.1016\/j.biomaterials.2020.119987_bib3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11427-017-9269-8","article-title":"GPR54 deficiency reduces the Treg population and aggravates experimental autoimmune encephalomyelitis in mice","volume":"61","author":"Xing","year":"2018","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.biomaterials.2020.119987_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41423-019-0221-5","article-title":"Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE","volume":"16","author":"Van Kaer","year":"2019","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.biomaterials.2020.119987_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.119987_bib6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","article-title":"European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis","volume":"49","author":"Comi","year":"2001","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.biomaterials.2020.119987_bib7","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-Controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biomaterials.2020.119987_bib8","first-page":"911","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, New Engl","volume":"354","author":"Rudick","year":"2006","journal-title":"J. Med."},{"issue":"9856","key":"10.1016\/j.biomaterials.2020.119987_bib9","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"9350","key":"10.1016\/j.biomaterials.2020.119987_bib10","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mims, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biomaterials.2020.119987_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.biomaterials.2020.119987_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2015.02.003","article-title":"Nanoparticle-based autoimmune disease therapy","volume":"160","author":"Serra","year":"2015","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.biomaterials.2020.119987_bib13","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ymthe.2017.03.032","article-title":"Peptide-conjugated nanoparticles reduce positive co-stimulatory expression and T cell activity to induce tolerance","volume":"25","author":"Kuo","year":"2017","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.biomaterials.2020.119987_bib14","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1021\/acsnano.8b06575","article-title":"Cytomembrane infused polymer accelerating delivery of myelin antigen peptide to treat experimental autoimmune encephalomyelitis","volume":"12","author":"Li","year":"2018","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biomaterials.2020.119987_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nano.2016.09.007","article-title":"An antigen-encapsulating nanoparticle platform for TH1\/17 immune tolerance therapy","volume":"13","author":"McCarthy","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biomaterials.2020.119987_bib16","doi-asserted-by":"crossref","first-page":"119432","DOI":"10.1016\/j.biomaterials.2019.119432","article-title":"Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease","volume":"222","author":"Saito","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2020.119987_bib17","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.nano.2018.10.001","article-title":"Overcoming challenges in treating autoimmuntity: development of tolerogenic immune-modifying nanoparticles","volume":"18","author":"Pearson","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.119987_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrd.2015.14","article-title":"Central nervous system myeloid cells as drug targets: current status and translational challenges","volume":"15","author":"Biber","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.119987_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1039\/C5BM00383K","article-title":"Strategies for transporting nanoparticles across the blood-brain barrier","volume":"4","author":"Zhang","year":"2016","journal-title":"Biomater Sci"},{"issue":"6","key":"10.1016\/j.biomaterials.2020.119987_bib20","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1021\/acsnano.9b01004","article-title":"Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders","volume":"13","author":"Riazifar","year":"2019","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.biomaterials.2020.119987_bib21","doi-asserted-by":"crossref","first-page":"E1194","DOI":"10.1073\/pnas.1714948115","article-title":"IL-1beta enables CNS access to CCR2(hi) monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells","volume":"115","author":"Pare","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.biomaterials.2020.119987_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/14737159.2013.819216","article-title":"Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease","volume":"13","author":"Lameijer","year":"2013","journal-title":"Expert Rev. Mol. Diagn"},{"issue":"11","key":"10.1016\/j.biomaterials.2020.119987_bib23","doi-asserted-by":"crossref","first-page":"10621","DOI":"10.1021\/acsnano.8b05950","article-title":"Nanoparticles for immune stimulation against infection, cancer, and autoimmunity","volume":"12","author":"Singha","year":"2018","journal-title":"ACS Nano"},{"issue":"30","key":"10.1016\/j.biomaterials.2020.119987_bib24","doi-asserted-by":"crossref","first-page":"14947","DOI":"10.1073\/pnas.1820276116","article-title":"Intravascular innate immune cells reprogrammed via intravenous nanoparticles to promote functional recovery after spinal cord injury","volume":"116","author":"Park","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.biomaterials.2020.119987_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01643","article-title":"Functional impairment of mononuclear phagocyte system by the human respiratory syncytial virus","volume":"8","author":"Bohmwald","year":"2017","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.biomaterials.2020.119987_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7150\/thno.6617","article-title":"Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles","volume":"3","author":"Zheng","year":"2013","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.biomaterials.2020.119987_bib27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/smll.200901515","article-title":"HDL\u2010Mimicking peptide\u2013lipid nanoparticles with improved tumor targeting","volume":"6","author":"Zhang","year":"2010","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2020.119987_bib28","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1002\/anie.200903112","article-title":"Biomimetic nanocarrier for direct cytosolic drug delivery","volume":"48","author":"Zhang","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biomaterials.2020.119987_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tifs.2018.01.016","article-title":"Health perspectives of a bioactive compound curcumin: a review","volume":"74","author":"Rauf","year":"2018","journal-title":"Trends Food Sci. Technol."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.119987_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10072-017-3149-5","article-title":"Therapeutic potential of curcumin for multiple sclerosis","volume":"39","author":"Qureshi","year":"2018","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.119987_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.intimp.2010.08.013","article-title":"Curcumin has bright prospects for the treatment of multiple sclerosis","volume":"11","author":"Xie","year":"2011","journal-title":"Int. Immunopharm."},{"issue":"5","key":"10.1016\/j.biomaterials.2020.119987_bib32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.intimp.2009.01.025","article-title":"Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production","volume":"9","author":"Xie","year":"2009","journal-title":"Int. Immunopharm."},{"issue":"1","key":"10.1016\/j.biomaterials.2020.119987_bib33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.celrep.2016.11.083","article-title":"Opposing functions of microglial and macrophagic TNFR2 in the pathogenesis of experimental autoimmune encephalomyelitis","volume":"18","author":"Gao","year":"2017","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.biomaterials.2020.119987_bib34","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1128\/MCB.20.11.4106-4114.2000","article-title":"Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion","volume":"20","author":"Jung","year":"2000","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.biomaterials.2020.119987_bib35","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/nprot.2006.285","article-title":"Active induction of experimental allergic encephalomyelitis","volume":"1","author":"Stromnes","year":"2006","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.biomaterials.2020.119987_bib36","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajpath.2012.05.011","article-title":"Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod","volume":"181","author":"Mishra","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biomaterials.2020.119987_bib37","doi-asserted-by":"crossref","first-page":"11541","DOI":"10.1038\/ncomms11541","article-title":"Experimental priming of encephalitogenic Th1\/Th17 cells requires pertussis toxin-driven IL-1beta production by myeloid cells","volume":"7","author":"Ronchi","year":"2016","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.biomaterials.2020.119987_bib38","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/nn.2887","article-title":"Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool","volume":"14","author":"Ajami","year":"2011","journal-title":"Nat. Neurosci."},{"issue":"12","key":"10.1016\/j.biomaterials.2020.119987_bib39","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.4049\/jimmunol.174.12.8116","article-title":"Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-\u03baB as potential targets","volume":"174","author":"Kim","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2020.119987_bib40","doi-asserted-by":"crossref","first-page":"1850025","DOI":"10.1142\/S1793545818500256","article-title":"Optical in vivo and ex vivo imaging of glioma cells migration via the cerebral vessels: prospective clinical application of the beta2-adrenoreceptors blockade for glioma treatment","volume":"11","author":"Pavlova","year":"2018","journal-title":"J. Innov. Opt. Health Sci."},{"key":"10.1016\/j.biomaterials.2020.119987_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.brainres.2015.04.002","article-title":"Progesterone attenuates thrombin-induced endothelial barrier disruption in the brain endothelial cell line bEnd.3: the role of tight junction proteins and the endothelial protein C receptor","volume":"1613","author":"Hun Lee","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.biomaterials.2020.119987_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.biomaterials.2014.10.068","article-title":"Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease","volume":"38","author":"Park","year":"2015","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.biomaterials.2020.119987_bib43","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/smll.201302825","article-title":"Polyhydroxylated metallofullerenols stimulate IL-1beta secretion of macrophage through TLRs\/MyD88\/NF-kappaB pathway and NLRP(3) inflammasome activation","volume":"10","author":"Chen","year":"2014","journal-title":"Small"},{"issue":"6","key":"10.1016\/j.biomaterials.2020.119987_bib44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of curcumin: problems and promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol. Pharm."},{"issue":"47","key":"10.1016\/j.biomaterials.2020.119987_bib45","doi-asserted-by":"crossref","first-page":"32159","DOI":"10.1021\/acsami.6b10175","article-title":"Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy","volume":"8","author":"Cui","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.biomaterials.2020.119987_bib46","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0885328218815328","article-title":"A novel curcumin-loaded nanoparticle restricts atherosclerosis development and promotes plaques stability in apolipoprotein E deficient mice","volume":"33","author":"Meng","year":"2019","journal-title":"J. Biomater. Appl."},{"issue":"11","key":"10.1016\/j.biomaterials.2020.119987_bib47","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jnutbio.2011.10.002","article-title":"Differential regulation of CD4+ T helper cell responses by curcumin in experimental autoimmune encephalomyelitis","volume":"23","author":"Kanakasabai","year":"2012","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.biomaterials.2020.119987_bib48","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neuropharm.2015.07.013","article-title":"Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair","volume":"99","author":"Mohajeri","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biomaterials.2020.119987_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2018.03.018","article-title":"Curcumin-loaded nanoparticles ameliorate glial activation and improve myelin repair in lyolecithin-induced focal demyelination model of rat corpus callosum","volume":"674","author":"Naeimi","year":"2018","journal-title":"Neurosci. Lett."},{"issue":"8","key":"10.1016\/j.biomaterials.2020.119987_bib50","doi-asserted-by":"crossref","first-page":"12237","DOI":"10.1002\/jcp.27965","article-title":"Curcumin as a therapeutic candidate for multiple sclerosis: molecular mechanisms and targets","volume":"234","author":"Ghanaatian","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"8","key":"10.1016\/j.biomaterials.2020.119987_bib51","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1194\/jlr.C078618","article-title":"Anti-inflammatory liaisons: T regulatory cells and HDL","volume":"58","author":"Sorci-Thomas","year":"2017","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2020.119987_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biomaterials.2020.119987_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00281","article-title":"Tolerogenic nanoparticles induce antigen-specific regulatory T cells and provide therapeutic efficacy and transferrable tolerance against experimental autoimmune encephalomyelitis","volume":"9","author":"LaMothe","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.119987_bib54","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/nn405033r","article-title":"A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease","volume":"8","author":"Hunter","year":"2014","journal-title":"ACS Nano"},{"issue":"17","key":"10.1016\/j.biomaterials.2020.119987_bib55","article-title":"Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease (vol 114, pg 3157, 2017)","volume":"114","author":"Pishesha","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.biomaterials.2020.119987_bib56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1021\/acs.bioconjchem.7b00624","article-title":"Conjugation of transforming growth factor beta to antigen-loaded poly(lactide-co-glycolide) nanoparticles enhances efficiency of antigen-specific tolerance","volume":"29","author":"Casey","year":"2018","journal-title":"Bioconjugate Chem."},{"issue":"219","key":"10.1016\/j.biomaterials.2020.119987_bib57","doi-asserted-by":"crossref","first-page":"219ra7","DOI":"10.1126\/scitranslmed.3007563","article-title":"Therapeutic inflammatory monocyte modulation using immune-modifying microparticles","volume":"6","author":"Getts","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2020.119987_bib58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2019.02.025","article-title":"Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation","volume":"300","author":"Saito","year":"2019","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.biomaterials.2020.119987_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07250-6","article-title":"MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma","volume":"9","author":"Wu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2020.119987_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biomaterials.2019.04.026","article-title":"Scaffolds biomimicking macrophages for a glioblastoma NIR-Ib imaging guided photothermal therapeutic strategy by crossing blood-brain barrier","volume":"211","author":"Lai","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2020.119987_bib61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biomaterials.2017.06.017","article-title":"Macrophages with cellular backpacks for targeted drug delivery to the brain","volume":"140","author":"Klyachko","year":"2017","journal-title":"Biomaterials"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961220302337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961220302337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:51:12Z","timestamp":1758905472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961220302337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":61,"alternative-id":["S0142961220302337"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119987","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119987"}}